MEDICINE FOR PREVENTING OR TREATING OPHTHALMIC DISEASE ASSOCIATED WITH ENHANCED INTRAOCULAR NEOVASCULARIZATION AND/OR INTRAOCULAR VASCULAR PERMEABILITY
Provided is a medicine for preventing or treating an ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability. The present inventors have made studies on medicines for preventing or treating ophthalmic diseases associated with enhanced intraocular neovascularization and/or intraocular vascular permeability. As a result, it is confirmed that a selective S1P receptor agonist having an agonistic activity on a S1P1 receptor has an activity to prevent intraocular neovascularization and an activity to prevent intraocular vascular permeability, and the present invention is accomplished. A compound according to the present invention, which is a selective S1P receptor agonist having an agonistic activity on a S1P1 receptor or a pharmaceutically acceptable salt thereof has an activity to prevent intraocular neovascularization and intraocular vascular permeability, and can be used as a prophylactic and/or therapeutic agent for exudative age-related macular degeneration, diabetic retinopathy, diabetic macular edema, myopic choroidal neovascularization, retinal artery occlusion, retinal vein occlusion, neovascular glaucoma or the like.
